Drug Search Results
More Filters [+]

Idebenone

Alternative Names: idebenone, raxone
Latest Update: 2024-04-25
Latest Update Note: News Article

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Turkey | Ukraine | United Kingdom | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: Santhera
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Idebenone

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Other

Phase 2: Optic Atrophy, Autosomal Dominant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OPA1

P2

Active, not recruiting

Optic Atrophy, Autosomal Dominant

2024-07-21

CTR20220888

P3

Not yet recruiting

Other

None

Recent News Events